SFE Investment Counsel Has $3.95 Million Stock Holdings in Danaher Co. (NYSE:DHR)

SFE Investment Counsel boosted its position in shares of Danaher Co. (NYSE:DHR) by 2.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 17,227 shares of the conglomerate’s stock after purchasing an additional 357 shares during the quarter. SFE Investment Counsel’s holdings in Danaher were worth $3,954,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Heck Capital Advisors LLC acquired a new position in shares of Danaher in the 4th quarter valued at $27,000. Decker Retirement Planning Inc. bought a new position in Danaher in the fourth quarter valued at approximately $31,000. Golden State Wealth Management LLC bought a new stake in Danaher in the 4th quarter valued at $31,000. Strategic Financial Concepts LLC bought a new position in Danaher during the 4th quarter worth about $31,000. Finally, Pineridge Advisors LLC raised its stake in shares of Danaher by 63.3% in the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after purchasing an additional 57 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 11.10% of the company’s stock.

Danaher Price Performance

Danaher stock opened at $202.22 on Thursday. The company has a market capitalization of $146.06 billion, a price-to-earnings ratio of 38.30, a PEG ratio of 2.68 and a beta of 0.83. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12 month low of $196.80 and a 12 month high of $281.70. The stock’s 50 day moving average is $230.49 and its 200-day moving average is $250.28.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the business posted $2.09 EPS. Equities research analysts expect that Danaher Co. will post 7.67 EPS for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were paid a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.53%. The ex-dividend date was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is 20.45%.

Analyst Upgrades and Downgrades

DHR has been the subject of several recent research reports. Barclays reduced their price objective on Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Robert W. Baird reduced their price target on Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Scotiabank initiated coverage on shares of Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price objective on the stock. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research report on Thursday, October 31st. Finally, Stephens reaffirmed an “overweight” rating and issued a $315.00 target price on shares of Danaher in a research report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.